Introduction {#s1}
============

Despite their type-specific features, cancers share some common traits, or "hallmarks," related to, e.g., the abilities of some cancer cells to divide uncontrollably or to invade surrounding tissues [@pcbi.1002920-Hanahan1]. Furthermore, it has been recognized that gene expression signatures resulting from analysis of cancer datasets can serve as surrogates of cancer phenotypes [@pcbi.1002920-Nevins1]. Therefore, it is reasonable to hypothesize that computational analysis of rich biomolecular cancer datasets may reveal signatures that are shared across many cancer types and are associated with specific cancer phenotypes. Such rich datasets become publicly available at an increasing rate from many sources, such as The Cancer Genome Atlas (TCGA). However, attempts to identify any such robust "bioinformatic hallmarks" of cancer have so far been largely unsuccessful.

Gene signatures may occasionally be found to exhibit similarities across multiple cancer types. However, to our knowledge no algorithm has ever produced a set of nearly identical signatures after independently and separately analyzing datasets from different cancer types.

There are various ways by which modules of co-expressed genes can be identified from rich datasets, some of which may be within the context of regulatory network discovery [@pcbi.1002920-Segal1]. Clustering approaches can classify a selected set of genes into subsets each of which contains mutually related genes. Related techniques can also be used to classify samples into cancer subtypes [@pcbi.1002920-Collisson1]--[@pcbi.1002920-Cancer1], each characterized by a set of characteristic genes. One of the most powerful computational approaches for this task has been nonnegative matrix factorization (NMF) [@pcbi.1002920-Brunet1] combined with consensus clustering [@pcbi.1002920-Monti1], resulting in successful subtype identification in several types of cancer.

The main objective addressed by techniques such as NMF is to reduce dimensionality by identifying a number of metagenes jointly representing the gene expression dataset as accurately as possible, in lieu of the whole set of individual genes. Each metagene in NMF is defined as a positive linear combination of the individual genes, so that its expression level is an accordingly weighted average of the expression levels of the individual genes. The identity of each resulting metagene is influenced by the presence of other metagenes within the objective of overall dimensionality reduction achieved by joint optimization.

By contrast, if the aim is exclusively to identify metagenes as surrogates of biomolecular events, then a fully unconstrained algorithm should be devised, without any effort to achieve dimensionality reduction, classification, mutual exclusivity, orthogonality, regulatory interaction inference, etc.

We can consider, for example, a hypothetical case in which we have found a cluster consisting of a number of co-expressed genes in a rich gene expression dataset. We may wish to scrutinize and "sharpen" this co-expression trying to identify the "heart" (core) of the genes that are most strongly co-expressed in that case. In the absence of a defining phenotype, we can continue applying an unsupervised methodology, as follows: We can first define a consensus metagene from the average expression levels of all genes in the cluster, and rank all the individual genes in terms of their association (defined numerically by some form of correlation) with that metagene. We can then replace the member genes of the cluster with an equal number of the top-ranked genes. Some of the original genes may naturally remain as members of the cluster, but some may be replaced, as this process will "attract" some other genes that are more strongly correlated with the cluster. We can now define a new metagene defined by the average expression levels of the genes in the newly defined cluster, and re-rank all the individual genes in terms of their association with that new metagene; and so on. It is intuitively reasonable to expect that this iterative process will eventually converge to a cluster that contains precisely the genes that are most associated with the metagene of the same cluster, so that any other individual genes will be less strongly associated with the metagene. We can think of this particular cluster defined by the convergence of this iterative process as an "attractor," i.e., a module of co-expressed genes to which many other gene sets with close but not identical membership will converge using the same computational methodology.

The above description represents a simplified conceptual introduction of the computational methodology presented in this paper. Rather than using the average of the expression values in gene clusters of a particular size, the "attractors" are metagenes defined as weighted averages of all genes where each individual gene has a nonnegative weight, just like the metagenes defined using NMF [@pcbi.1002920-Brunet1]. We found that, given a rich (loosely defined as containing at least 200 samples) dataset represented by a gene expression matrix, such metagenes can be naturally identified as stable and precise attractors using a simple iterative approach. We experimentally verified these nice convergence properties without any exception after trying numerous times the method described in this paper on such rich datasets.

This methodology is totally unsupervised, as it does not make use of any phenotypic association. As we show in this paper, however, once identified, a metagene attractor is likely to be found associated with a phenotype.

We found that several attractor metagenes are present in nearly identical form in multiple cancer types. This provides an additional opportunity to combine the powers of a large number of rich datasets to focus, at an even sharper level, on the core genes of the underlying mechanism. For example, this methodology can precisely point to the causal (driver) oncogenes within amplicons to be among very few candidate genes. Importantly, this can be done from rich gene expression data, which already exist in abundance, without making any use of sequencing data.

We identified several attractors, each of which has the potential to lead to corresponding testable biological hypotheses after scrutinizing their top-ranked genes and finding a putative underlying mechanism. For the purposes of this paper we present the general methodology for the benefit of the research community together with a listing of the attractors in six datasets from three cancer types (ovarian, colon, breast).

Here, we focus on a few interesting cancer-associated attractors that we found present in multiple cancer types. Particular emphasis is given to what we consider to be three key "bioinformatic hallmarks" of cancer, related to the ability of cancer cells to invade surrounding tissues; to divide uncontrollably; and the ability of the organism to recruit the immune system to fight cancer: a tumor stage-associated mesenchymal transition attractor, a tumor grade-associated mitotic chromosomal instability (mitotic CIN) attractor, and a lymphocyte-specific attractor.

Results {#s2}
=======

Derivation of Attractor Metagenes {#s2a}
---------------------------------

Given a nonnegative measure of pairwise association between genes and , we define an attractor metagene to be a linear combination of the individual genes with weights . The association measure is assumed to have minimum possible value 0 and maximum possible value 1, so the same is true for the weights. It is also assumed to be scale-invariant, therefore it is not necessary for the weights to be normalized so that they add to 1, and the metagenes can still be thought of as expressing a normalized weighted average of the expression levels of the individual genes. See [Materials and Methods](#s4){ref-type="sec"} for the choice of the measure .

According to this definition, the genes with the highest weights in an attractor metagene will have the highest association with the metagene (and, by implication, they will tend to be highly associated among themselves) and so they will often represent a biomolecular event reflected by the co-expression of these top genes. This can happen, e.g., when a biological mechanism is activated, or when a copy number variation (CNV), such as an amplicon, is present, in some of the samples included in the expression matrix. In the following we use the term "attractor" for simplicity to refer to an attractor metagene, and the term "top genes" to refer to the genes with the highest weights in the attractor. The definition of an attractor metagene can readily be generalized to include features other than gene expression, such as methylation values. It can also be used in datasets of any objects (not necessarily genes) characterized by any type of feature vectors, with applications in other disciplines, such as social and economic sciences.

The computational problem of identifying attractor metagenes given an expression matrix can be addressed heuristically using a simple iterative process: Starting from a particular seed (or "attractee") metagene , a new metagene is defined in which the new weights are . The same process is then repeated in the next iteration resulting in a new set of weights, and so forth. In all gene expression datasets that we tried we found that this process converges to a limited number of stable attractors. Each attractor is defined by a precise set of weights, which are reached with high accuracy typically within 10 or 20 iterations.

This algorithmic behavior with nice convergence properties is not surprising, because if a metagene represents co-expressed genes, then the next iteration will naturally "attract" other similarly co-expressed genes, and so forth, until there are no other genes more associated with the top genes than those genes themselves. Furthermore, the set of the few genes with the highest weight are likely to represent the "heart" (core) of the underlying biomolecular event. In support of this concept, the association of any of the top-ranked individual genes with the attractor metagene is consistently and significantly higher than the pairwise association between any of these genes, suggesting that the set of these top genes jointly comprise a proxy representing a biomolecular event better than each of the individual genes would.

Indeed, related versions of the signatures identified by attractors in this paper have been previously identified in various contexts in individual cancer types, often intermingled with additional genes. However, the contribution of our work is that these signatures are found as pan-cancer biomolecular events, sharply pointing to the underlying mechanism. Therefore the top genes of the attractors will be appropriate for being used as biomarkers or for understanding the underlying biology. For example, one of the attractors that we identified (the "mitotic chromosomal instability" attractor, described below) has previously been found in approximate forms among sets of genes described generally [@pcbi.1002920-Whitfield1] as "proliferation" or "cell cycle related" markers, while the actual attractor points much more sharply to particular elements in the structure of the kinetochore-microtubule interface.

A reasonable implementation of an "exhaustive" search of attractor metagenes is to start from each individual gene as a seed ("attractee") assigning a weight of 1 to that gene, and 0 to all the other genes. Each gene participating in a particular co-expression event will then lead to the same attractor when used as attractee. The computational implementation of the algorithm is described in [Materials and Methods](#s4){ref-type="sec"}. We note that a dual method can be used to identify attractor "metasamples" as representatives of subtypes, and we can also combine such metasamples with the attractor metagenes in various ways to achieve biclustering, but this topic is not examined in this paper.

We analyzed six datasets, two from ovarian cancer, two from breast cancer and two from colon cancer (Supplementary [Text S1](#pcbi.1002920.s008){ref-type="supplementary-material"}). In each case, we identified general (Supplementary [Table S1](#pcbi.1002920.s001){ref-type="supplementary-material"}) and genomically localized (Supplementary [Table S2](#pcbi.1002920.s002){ref-type="supplementary-material"}) attractors and we found that many among them appear in similar forms in all six datasets using particular merging and ranking criteria in each case ([Materials and Methods](#s4){ref-type="sec"} and Supplementary [Text S1](#pcbi.1002920.s008){ref-type="supplementary-material"}). Following are descriptions of some of our results, starting with the three strongest multi-cancer attractors.

Mesenchymal Transition Attractor Metagene {#s2b}
-----------------------------------------

This attractor contains mostly epithelial-mesenchymal transition (EMT)-associated genes. [Table 1](#pcbi-1002920-t001){ref-type="table"} provides a listing of the top 100 genes based on their average mutual information ([Materials and Methods](#s4){ref-type="sec"}) with their corresponding attractor metagenes.

10.1371/journal.pcbi.1002920.t001

###### Top 100 genes of the mesenchymal transition attractor based on six datasets.

![](pcbi.1002920.t001){#pcbi-1002920-t001-1}

  Rank    Gene Symbol   Avg MI   Rank   Gene Symbol   Avg MI
  ------ ------------- -------- ------ ------------- --------
  1         COL5A2      0.814     51       SULF1      0.505
  2          VCAN       0.775     52       LOXL1      0.502
  3          SPARC      0.766     53       PRRX1      0.502
  4          THBS2      0.758     54     PPAPDC1A     0.499
  5          FBN1       0.749     55      COL10A1     0.498
  6         COL1A2      0.749     56      ITGA11      0.495
  7         COL5A1      0.747     57        NTM       0.494
  8           FAP       0.734     58       MXRA8      0.494
  9          AEBP1      0.711     59       FIBIN      0.493
  10         CTSK       0.709     60       WISP1      0.483
  11        COL3A1      0.688     61       RCN3       0.483
  12        COL1A1      0.683     62      TNFAIP6     0.481
  13       SERPINF1     0.674     63       ECM2       0.480
  14        COL6A3      0.669     64       HTRA1      0.480
  15         CDH11      0.663     65      EFEMP2      0.478
  16        GLT8D2      0.658     66       MXRA5      0.474
  17          LUM       0.654     67       ACTA2      0.472
  18         MMP2       0.654     68        LOX       0.470
  19          DCN       0.650     69      ITGBL1      0.466
  20        CCDC80      0.637     70       PMP22      0.465
  21         POSTN      0.631     71       P4HA3      0.464
  22        CTHRC1      0.616     72       PTRF       0.463
  23        ADAM12      0.613     73       CALD1      0.460
  24        COL6A2      0.608     74       HEG1       0.458
  25         MSRB3      0.608     75       NEXN       0.455
  26        OLFML2B     0.607     76       NID2       0.455
  27         INHBA      0.600     77       TAGLN      0.455
  28         FSTL1      0.600     78      FAM26E      0.452
  29         SFRP2      0.596     79      ZNF521      0.452
  30         SNAI2      0.577     80       SFRP4      0.451
  31       CRISPLD2     0.574     81       PALLD      0.450
  32        PCOLCE      0.571     82      OLFML1      0.447
  33        PDGFRB      0.567     83      FILIP1L     0.447
  34          BGN       0.565     84       TIMP3      0.445
  35        COL12A1     0.560     85       SPON2      0.443
  36        ANGPTL2     0.555     86      SPOCK1      0.443
  37         COPZ2      0.553     87      COL8A2      0.441
  38         CMTM3      0.549     88       GPC6       0.438
  39         ASPN       0.547     89       PDPN       0.437
  40          FN1       0.545     90       GFPT2      0.436
  41        CNRIP1      0.540     91       LHFP       0.436
  42         FNDC1      0.538     92       GREM1      0.436
  43        LRRC15      0.533     93      TGFB1I1     0.435
  44        COL11A1     0.529     94        C1S       0.433
  45        ANTXR1      0.528     95       EDNRA      0.432
  46         RAB31      0.527     96       GAS1       0.431
  47         FRMD6      0.524     97       NOX4       0.431
  48         TSHZ3      0.520     98       FBLN2      0.428
  49         THY1       0.519     99       TCF4       0.428
  50         NNMT       0.519    100       NUAK1      0.427

The consistency of the attractor is established by the fact (Supplementary [Table S1](#pcbi.1002920.s001){ref-type="supplementary-material"}) that there are many genes (COL5A2, COL1A2, SPARC, CTSK, FBN1, VCAN, AEBP1, SERPINF1) that are among the top 50 genes in the attractors of *all* six datasets. The corresponding *P* value is less than 10^−7^ by permutation test ([Materials and Methods](#s4){ref-type="sec"}). Similar results are found in other solid cancer types in all cases that we tried.

This is a stage-associated attractor, in which the signature is significantly present only when a particular level of invasive stage, specific to each cancer type, has been reached. Supplementary [Table S3](#pcbi.1002920.s003){ref-type="supplementary-material"} demonstrates this phenomenon in three cancer datasets from different types (breast, ovarian and colon) that were annotated with clinical staging information, by providing a listing of differentially expressed genes, ranked by fold change, when ductal carcinoma in situ (DCIS) progresses to invasive ductal carcinoma; ovarian cancer progresses to stage III; and colon cancer progresses to stage II. In all three cases, the attractor is highly enriched among the top genes. Specifically, among the top 100 differentially expressed genes, the number of attractor genes included in [Table 1](#pcbi-1002920-t001){ref-type="table"} is 47 in breast cancer, 42 in ovarian cancer and 37 in colon cancer. The corresponding *P* values are 2×10^−93^, 4×10^−80^ and 8×10^−78^, respectively.

This attractor has been previously identified with remarkable accuracy as representing a particular kind of mesenchymal transition of cancer cells present in all types of solid cancers tested leading to a published list of top 64 genes [@pcbi.1002920-Kim1], [@pcbi.1002920-Anastassiou1]. This list was generated using a supervised algorithm using association with tumor stage. Indeed 52 of these top 64 genes also appear in [Table 1](#pcbi-1002920-t001){ref-type="table"} (*P*\<10^−114^), and furthermore all top 19 genes of [Table 1](#pcbi-1002920-t001){ref-type="table"} are among the 64. We found that most of the genes of the signature were expressed by the cancer cells themselves, and not by the surrounding stroma, at least in a neuroblastoma xenograft model that we tried [@pcbi.1002920-Anastassiou1]. We also found that the signature is associated with prolonged time to recurrence in glioblastoma [@pcbi.1002920-Cheng1]. Related versions of the same signature were previously found to be associated with resistance to neoadjuvant therapy in breast cancer [@pcbi.1002920-Farmer1]. These results are consistent with the finding that EMT induces cancer cells to acquire stem cell properties [@pcbi.1002920-Mani1]. It has been hypothesized that EMT is a key mechanism for cancer cell invasiveness and motility [@pcbi.1002920-Hay1]--[@pcbi.1002920-Kalluri1]. The attractor, however, appears to represent a more general phenomenon of transdifferentiation present even in nonepithelial cancers such as neuroblastoma, glioblastoma and Ewing\'s sarcoma.

Although similar signatures are often labeled as "stromal," because they contain many stromal markers such as α-SMA and fibroblast activation protein, the fact that most of the genes of the signature were expressed by xenografted cancer cells [@pcbi.1002920-Anastassiou1], and not by mouse stromal cells, suggests that this particular attractor of coordinately expressed genes represents cancer cells having undergone a mesenchymal transition. The signature may indicate a non-fibroblastic transition, as occurs in glioblastoma, in which case collagen *COL11A1* is not co-expressed with the other genes of the attractor. We have hypothesized that a full fibroblastic transition of the cancer cells occurs when cancer cells encounter adipocytes [@pcbi.1002920-Anastassiou1], in which case they may well assume the duties of cancer-associated fibroblasts (CAFs) in some tumors [@pcbi.1002920-Hanahan1]. In that case, the best proxy of the signature [@pcbi.1002920-Kim1] is *COL11A1* and the strongly co-expressed genes *THBS2* and *INHBA*. Indeed, the 64 genes of the previously identified signature were found from multi-cancer analysis [@pcbi.1002920-Kim1] as the genes whose expression is consistently most associated with that of *COL11A1*.

The only EMT-inducing transcription factor found upregulated in the xenograft model [@pcbi.1002920-Anastassiou1] is SNAI2 (Slug), and it is also the one most associated with the signature in publicly available datasets. We also found that the microRNAs most highly associated with this attractor are miR-214, miR-199a, and miR-199b. Interestingly, miR-214 and miR-199a were found to be jointly regulated by another EMT-inducing transcription factor, TWIST1 [@pcbi.1002920-Yin1].

The expression of the mesenchymal transition attractor indicates that the tumor is actively invasive at the specific sample site, so its prognostic value is cancer type and stage specific. As an example, we analyzed an oral squamous cell carcinoma dataset deposited in the Gene Expression Omnibus (GEO) under accession number GSE25104. The corresponding Kaplan-Meier survival curve (*P* = 0.0066) is shown in [Figure 1](#pcbi-1002920-g001){ref-type="fig"}.

![Kaplan-Meier curves of mesenchymal transition attractor metagene in oral squamous cell carcinoma dataset.\
Gene expression data from 57 patients (GSE25104) were divided into two groups: high mesenchymal transition metagene level and low mesenchymal transition metagene level depending on whether the metagene expression value exceeding the mean of the 57 patients. The *P* value of the association was determined by log-rank test.](pcbi.1002920.g001){#pcbi-1002920-g001}

Mitotic CIN Attractor Metagene {#s2c}
------------------------------

This attractor contains mostly kinetochore-associated genes. [Table 2](#pcbi-1002920-t002){ref-type="table"} provides a listing of the top 100 genes based on their average mutual information ([Materials and Methods](#s4){ref-type="sec"}) with their corresponding attractor metagenes, starting from *CENPA*, which encodes for a histone H3-like centromeric protein.

10.1371/journal.pcbi.1002920.t002

###### Top 100 genes of the mitotic CIN attractor based on six datasets.

![](pcbi.1002920.t002){#pcbi-1002920-t002-2}

  Rank    Gene Symbol   Avg MI   Rank   Gene Symbol   Avg MI
  ------ ------------- -------- ------ ------------- --------
  1          CENPA      0.720     51       CDCA8      0.532
  2         DLGAP5      0.693     52       CDC45      0.528
  3          MELK       0.684     53      KIF18A      0.524
  4          BUB1       0.674     54       HMMR       0.506
  5          KIF2C      0.660     55       TOP2A      0.505
  6         KIF20A      0.658     56       CENPF      0.503
  7          KIF4A      0.656     57       ZWINT      0.503
  8          CCNA2      0.654     58       PLK1       0.501
  9          CCNB2      0.652     59     RAD51AP1     0.501
  10         NCAPG      0.649     60      FAM83D      0.498
  11          TTK       0.642     61       E2F8       0.497
  12         CEP55      0.638     62       CENPE      0.497
  13         CCNB1      0.632     63       MKI67      0.492
  14         CDK1       0.629     64       CENPN      0.491
  15         HJURP      0.626     65      MAD2L1      0.489
  16         CDC20      0.624     66       CHEK1      0.486
  17         CDCA5      0.615     67       GTSE1      0.477
  18         NCAPH      0.615     68       RAD51      0.475
  19         BUB1B      0.609     69       SGOL2      0.474
  20         KIF23      0.592     70      PARPBP      0.469
  21         KIF11      0.591     71      TRIP13      0.467
  22         BIRC5      0.589     72      SHCBP1      0.465
  23         NUF2       0.587     73        DTL       0.465
  24         TPX2       0.586     74       CENPL      0.462
  25         AURKB      0.582     75       FEN1       0.461
  26        RACGAP1     0.580     76       FANCI      0.461
  27        NUSAP1      0.580     77       FBXO5      0.459
  28         ASPM       0.579     78       ECT2       0.457
  29         MCM10      0.579     79       MND1       0.456
  30         PRC1       0.576     80      CDC25C      0.456
  31        DEPDC1B     0.572     81        PBK       0.456
  32         UBE2C      0.569     82       KPNA2      0.452
  33         UBE2T      0.567     83      RAD54L      0.452
  34         NEK2       0.566     84       ESPL1      0.447
  35         FOXM1      0.565     85       CDCA2      0.446
  36         NDC80      0.556     86      FAM64A      0.440
  37         CDCA3      0.556     87       CENPK      0.436
  38        FAM54A      0.553     88       MYBL2      0.435
  39         ANLN       0.551     89       SPAG5      0.434
  40         KIF15      0.548     90       EZH2       0.431
  41         STIL       0.547     91       SMC4       0.430
  42         EXO1       0.542     92       TACC3      0.428
  43         AURKA      0.540     93     C11orf82     0.427
  44         PTTG1      0.539     94       MASTL      0.426
  45         OIP5       0.539     95       ASF1B      0.426
  46         RRM2       0.539     96      PTTG3P      0.425
  47        DEPDC1      0.539     97       CENPW      0.424
  48         CDKN3      0.538     98       ORC1       0.424
  49         KIF14      0.537     99       HELLS      0.422
  50         SPC25      0.534    100        TK1       0.421

The consistency of the attractor is established by the fact (Supplementary [Table S1](#pcbi.1002920.s001){ref-type="supplementary-material"}) that there are many genes (CENPA, DLGAP5, KIF2C, CCNB2, MELK, CCNA2, KIF20A, HJURP, NUSAP1, BUB1, TTK, KIF11, NCAPH) that are among the top 50 genes in the attractors of all six datasets. The corresponding *P* value is less than 10^−7^ by permutation test ([Materials and Methods](#s4){ref-type="sec"}). Similar results are found in other solid cancer types in all cases that we tried.

Contrary to the stage-associated mesenchymal transition attractor, this is a grade-associated attractor, in which the signature is significantly present only when an intermediate level of tumor grade is reached. Supplementary [Table S4](#pcbi.1002920.s004){ref-type="supplementary-material"} demonstrates this phenomenon in three cancer datasets from different types (breast, ovarian and bladder) that were annotated with tumor grade information, by providing a listing of differentially expressed genes, ranked by fold change, when grade G2 is reached. In all three cases, the attractor is highly enriched among the top genes. Specifically, among the top 100 differentially expressed genes, the number of attractor genes included [Table 2](#pcbi-1002920-t002){ref-type="table"} is 40 in breast cancer, 38 in ovarian cancer and 27 in colon cancer. The corresponding *P* values are 4×10^−74^, 3×10^−69^ and 3×10^−49^, respectively. Consistently, a similar "gene expression grade index" signature [@pcbi.1002920-Sotiriou1] was previously found differentially expressed between histologic grade 3 and histologic grade 1 breast cancer samples. Furthermore, that same signature [@pcbi.1002920-Sotiriou1] was found capable of reclassifying patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence.

This attractor is associated with chromosomal instability (CIN), as evidenced from the fact that another similar gene set comprising a "signature of chromosomal instability" [@pcbi.1002920-Carter1] was previously derived from multiple cancer datasets purely by identifying the genes that are most correlated with a measure of aneuploidy in tumor samples. This led to a 70-gene signature referred to as "CIN70." Indeed 31 of these 70 genes appear in [Table 2](#pcbi-1002920-t002){ref-type="table"} (*P*\<10^−53^). However, several top genes of the attractor, such as *CENPA*, *DLGAP5*, *KIF2C*, *BUB1* and *CCNA2* are not present in the CIN70 list. Mitotic CIN is increasingly recognized [@pcbi.1002920-Schvartzman1] as a widespread multi-cancer phenomenon.

The attractor is characterized by overexpression of kinetochore-associated genes, which is known [@pcbi.1002920-Yuen1] to induce CIN. Overexpression of several of the genes of the attractor, such as the top gene *CENPA* [@pcbi.1002920-Amato1], as well as *MAD2L1* [@pcbi.1002920-Sotillo1] and *TPX2* [@pcbi.1002920-Heidebrecht1], has also been independently previously found associated with CIN. Included in the mitotic CIN attractor are key components of mitotic checkpoint signaling [@pcbi.1002920-OrrWeaver1], such as *BUB1B*, *MAD2L1* (aka *MAD2*), *CDC20*, and *TTK* (aka *MSP1*). Also among the genes in the attractor is *MKI67* (aka *Ki-67*), which has been widely used as a proliferation rate marker in cancer.

Among transcription factors, we found *MYBL2* (aka *B-Myb*) and *FOXM1* to be strongly associated with the attractor. They are already known to be sequentially recruited to promote late cell cycle gene expression [@pcbi.1002920-Sadasivam1] to prepare for mitosis.

Inactivation of the retinoblastoma (RB) tumor suppressor promotes CIN [@pcbi.1002920-Manning1] and the expression of the attractor signature. Indeed, a similar expression of a "proliferation gene cluster [@pcbi.1002920-Rosty1]" was found strongly associated with the human papillomavirus E7 oncogene, which abrogates RB protein function and activates E2F-regulated genes. Consistently, many among the genes of the attractor correspond to E2F pathway genes controlling cell division or proliferation. Among the E2F transcription factors, we found that E2F8 and E2F7 are most strongly associated with the attractor.

Lymphocyte-Specific Attractor Metagene {#s2d}
--------------------------------------

This attractor consists mainly of lymphocyte-specific genes with prominent presence of *CD53*, *PTPRC*, *LAPTM5*, *DOCK2*, *LCP2* and *IL10RA*. It is strongly associated with the expression of microRNA miR-142 as well as with particular hypermethylated and hypomethylated gene signatures [@pcbi.1002920-Andreopoulos1]. There is also significant overlap between the sets of hypomethylated and overexpressed genes, suggesting that their expression is triggered by hypomethylation. Gene set enrichment analysis reveals that the attractor is found enriched in genes known to be preferentially expressed in differentiation into lymphocytes [@pcbi.1002920-Lee1]. [Table 3](#pcbi-1002920-t003){ref-type="table"} provides a listing of the top 100 genes of the lymphocyte-specific attractor based on their average mutual information ([Materials and Methods](#s4){ref-type="sec"}) with their corresponding attractor metagenes.

10.1371/journal.pcbi.1002920.t003

###### Top 100 genes of the lymphocyte-specific attractor based on six datasets.

![](pcbi.1002920.t003){#pcbi-1002920-t003-3}

  Rank    Gene Symbol   Avg MI   Rank   Gene Symbol   Avg MI
  ------ ------------- -------- ------ ------------- --------
  1          PTPRC      0.782     51       NCF1       0.560
  2          CD53       0.768     52       CCL5       0.557
  3          LCP2       0.739     53       LST1       0.557
  4         LAPTM5      0.708     54       CD3D       0.553
  5          DOCK2      0.699     55       RCSD1      0.548
  6         IL10RA      0.699     56       FGL2       0.538
  7          CYBB       0.698     57       HCST       0.538
  8          CD48       0.691     58      MARCH1      0.538
  9          ITGB2      0.679     59      FERMT3      0.536
  10         EVI2B      0.675     60      FCGR2B      0.533
  11        MS4A6A      0.673     61      GIMAP5      0.530
  12         TFEC       0.659     62       MYO1F      0.530
  13          SLA       0.657     63       KLHL6      0.530
  14       TNFSF13B     0.657     64      GIMAP1      0.527
  15       C1orf162     0.656     65       CD163      0.524
  16        SAMSN1      0.652     66      CLEC7A      0.522
  17         PLEK       0.649     67       CCR1       0.518
  18         GMFG       0.647     68       GBP5       0.517
  19        GIMAP4      0.647     69       NCF2       0.516
  20         SASH3      0.645     70     HLA-DPA1     0.516
  21         EVI2A      0.638     71      RNASE6      0.515
  22         SRGN       0.638     72       CD14       0.515
  23         AIF1       0.636     73      FAM26F      0.511
  24         LAIR1      0.627     74        CD4       0.510
  25          FYB       0.625     75      FCGR1A      0.506
  26        FCER1G      0.623     76       GZMA       0.506
  27         MPEG1      0.621     77      GPR183      0.505
  28         CD86       0.621     78       CD84       0.505
  29         C3AR1      0.611     79       NKG7       0.504
  30         C1QB       0.608     80       C1QA       0.502
  31          CD2       0.606     81      CD300LF     0.500
  32         HCLS1      0.599     82       FPR3       0.499
  33          HCK       0.592     83       PARVG      0.496
  34         MNDA       0.587     84     TRAF3IP3     0.494
  35         CD37       0.587     85      TYROBP      0.492
  36         LY96       0.585     86       LPXN       0.492
  37         CCR5       0.585     87      GIMAP8      0.492
  38        ARHGAP9     0.580     88       MS4A7      0.490
  39         CD52       0.580     89       IL2RB      0.489
  40         GPR65      0.580     90      CD300A      0.488
  41        GIMAP6      0.578     91       IGSF6      0.488
  42        SLAMF8      0.577     92      SELPLG      0.488
  43         WIPF1      0.577     93      FCGR2A      0.487
  44        MS4A4A      0.574     94      NCKAP1L     0.483
  45       ARHGAP15     0.573     95       DOK2       0.483
  46        HAVCR2      0.567     96       CD247      0.481
  47       ARHGAP30     0.566     97       SELL       0.480
  48        CLEC4A      0.566     98       GZMK       0.479
  49         TAGAP      0.564     99       CCR2       0.479
  50         CYTIP      0.563    100       LY86       0.479

The gene membership of the attractor provides hints about the underlying immune mechanism, which could be valuable towards generating hypotheses for potential immunotherapies such as adoptive transfer of lymphocytes. For example, the presence of the signal-transducing *LCP2* (aka *SLP-76*) gene, together with the adaptor *FYB* (aka *ADAP*), suggests the formation of the SLP-76-ADAP adaptor module, which is known to regulate lymphocyte co-stimulation mediated by integrin ITGB2 (aka LFA-1), another prominent gene in the attractor [@pcbi.1002920-Wang1].

Association of the Three Main Attractor Metagenes with Prognosis in Breast Cancer {#s2e}
---------------------------------------------------------------------------------

We found that each of the above three main attractors under particular conditions is highly prognostic in breast cancer by analysing the METABRIC discovery breast cancer dataset [@pcbi.1002920-Curtis1] which includes both expression as well as survival data.

### Mesenchymal transition attractor {#s2e1}

In breast cancer, the mesenchymal transition attractor is expressed very early, as cancer becomes invasive. The presence of the attractor in a particular sample of high-stage tumor in not as informative, because of heterogeneity. On the other hand we found that the presence of the attractor in early-stage tumors is highly prognostic, consistent with the hypothesis that it indicates increased invasiveness. As shown in [Figure 2](#pcbi-1002920-g002){ref-type="fig"}, the Kaplan-Meier 15-year survival curves of the mesenchymal transition attractor using all samples does not show any significance. However, when we restrict the samples to early stage patients, defined as having no positive lymph nodes and tumor size less than 30 mm, the association between the attractor and survival became significant (*P* = 0.032).

![Kaplan-Meier curve of mesenchymal transition attractor metagenes in breast cancer dataset.\
The mesenchymal transition attractor metagene is most prominent in the early stage of breast cancer. The survival curve of the full dataset is insignificant (left). However, when the samples are restricted to only those at early stage (with no positive lymph nodes and tumor size less than 30 mm), the association between the mesenchymal transition attractor and the survival becomes significant (right), with *P* = 0.032.](pcbi.1002920.g002){#pcbi-1002920-g002}

### Mitotic CIN attractor {#s2e2}

The expression of the mitotic CIN attractor indicates that the tumor is dividing uncontrollably and therefore, in all cases, the attractor is highly prognostic for survival. The corresponding Kaplan-Meier 15-year survival curve (*P*\<2×10^−8^) is shown in [Figure 3](#pcbi-1002920-g003){ref-type="fig"}. Furthermore, we ranked all the genes in terms of the concordance index [@pcbi.1002920-Pencina1] between the survival and the individual gene\'s expression value from the same rich dataset. [Table 4](#pcbi-1002920-t004){ref-type="table"} shows the top 100 genes, within which 47 (indicated by underline and boldface), including the top six, are also among the genes shown in [Table 2](#pcbi-1002920-t002){ref-type="table"} (*P* = 2×10^−98^ by Fisher\'s exact test). This extraordinary enrichment (also note that eight among the top ten genes, including the top three, are among the genes of [Table 2](#pcbi-1002920-t002){ref-type="table"}) demonstrates that the members of the mitotic CIN attractor are, among all genes, the most prognostic ones, at least in breast cancer.

![Kaplan-Meier curve of mitotic CIN attractor metagene in breast cancer dataset.\
To evaluate the association between the mitotic CIN metagene expression and the 15-year survival, patients were divided into two groups: high mitotic CIN and low mitotic CIN. This binary expression level was determined by whether the mitotic CIN metagene expression value exceeding the mean of the patients. The *P* value of the association based on log-rank test is 1.8×10^−8^.](pcbi.1002920.g003){#pcbi-1002920-g003}

10.1371/journal.pcbi.1002920.t004

###### List of top-ranked genes in terms of survival concordance index of the METABRIC discovery dataset demonstrating enrichment of the mitotic CIN attractor.

![](pcbi.1002920.t004){#pcbi-1002920-t004-4}

  Rank       Gene Symbol       Concordance Index   Rank      Gene Symbol      Concordance Index
  ------ -------------------- ------------------- ------ ------------------- -------------------
  1        **[CDCA5]{.ul}**          0.670          51          PRR11               0.639
  2        **[AURKA]{.ul}**          0.663          52        LOC651816             0.638
  3       **[KIF20A]{.ul}**          0.662          53          KRT80               0.638
  4             TROAP                0.661          54        C15orf42              0.637
  5        **[UBE2C]{.ul}**          0.659          55          SGOL1               0.637
  6        **[AURKA]{.ul}**          0.658          56           GPI                0.637
  7       **[FAM83D]{.ul}**          0.657          57    **[CEP55]{.ul}**          0.637
  8             SHMT2                0.655          58    **[MCM10]{.ul}**          0.636
  9        **[UBE2C]{.ul}**          0.655          59         PKMYT1               0.635
  10       **[CCNB2]{.ul}**          0.653          60    **[CENPN]{.ul}**          0.635
  11       **[TPX2]{.ul}**           0.653          61        C20orf24              0.635
  12       **[EXO1]{.ul}**           0.653          62          SPC24               0.635
  13             ORC6                0.653          63          RIPK4               0.635
  14       **[CENPA]{.ul}**          0.653          64         TOMM40               0.634
  15           C1orf106              0.652          65     **[ANLN]{.ul}**          0.634
  16       **[GTSE1]{.ul}**          0.652          66          ADRM1               0.634
  17       **[MELK]{.ul}**           0.651          67    **[NCAPG]{.ul}**          0.633
  18            STIP1                0.651          68    **[CDCA8]{.ul}**          0.633
  19       **[SPC25]{.ul}**          0.649          69          AIF1L               0.633
  20       **[CENPA]{.ul}**          0.649          70          MRPS5               0.633
  21             GARS                0.649          71          GPR56               0.633
  22       **[MELK]{.ul}**           0.649          72          PEX13               0.633
  23             UCK2                0.648          73          ENO1                0.633
  24       **[HJURP]{.ul}**          0.648          74          NUTF2               0.633
  25       **[PTTG1]{.ul}**          0.647          75          MEMO1               0.632
  26             CBX2                0.646          76         TXNRD1               0.632
  27            CCNE1                0.646          77         SLC7A5               0.631
  28       **[PLK1]{.ul}**           0.646          78    **[FOXM1]{.ul}**          0.631
  29       **[KIF2C]{.ul}**          0.645          79    **[KIF14]{.ul}**          0.631
  30       **[CCNA2]{.ul}**          0.645          80        PPP1R14B              0.631
  31            GMPSP1               0.645          81    **[FAM54A]{.ul}**         0.630
  32       **[AURKB]{.ul}**          0.645          82        C20orf24              0.630
  33       **[BUB1]{.ul}**           0.644          83          SGOL1               0.630
  34      **[TRIP13]{.ul}**          0.643          84          NUP93               0.630
  35       **[FOXM1]{.ul}**          0.643          85         ZNF695               0.630
  36       **[CDC20]{.ul}**          0.643          86    **[BIRC5]{.ul}**          0.630
  37          LOC731049              0.642          87    **[CENPL]{.ul}**          0.630
  38             POLQ                0.642          88          SOX11               0.630
  39            GSK3B                0.642          89    **[KIF23]{.ul}**          0.629
  40            CCNE1                0.642          90         SLC52A2              0.629
  41       **[KIF4A]{.ul}**          0.641          91          AIF1L               0.629
  42       **[PRC1]{.ul}**           0.641          92     **[FEN1]{.ul}**          0.629
  43             LAD1                0.641          93         CDC25A               0.629
  44      **[FAM64A]{.ul}**          0.641          94    **[CDCA3]{.ul}**          0.628
  45            SAPCD2               0.641          95        TMEM132A              0.628
  46      **[RACGAP1]{.ul}**         0.641          96    **[CENPE]{.ul}**          0.628
  47            POLR2D               0.641          97          NACC2               0.628
  48            CKAP2L               0.640          98     **[TTK]{.ul}**           0.628
  49       **[PTTG1]{.ul}**          0.640          99         SNRPA1               0.628
  50             ECE2                0.639         100          MMP15               0.628

The 47 underlined genes are also among the top 100 genes of the mitotic CIN attractor ([Table 2](#pcbi-1002920-t002){ref-type="table"}).

### Lymphocyte-specific attractor {#s2e3}

We found the attractor to be strongly protective in ER-negative breast cancers. As shown in [Figure 4](#pcbi-1002920-g004){ref-type="fig"}, the Kaplan-Meier 15-year survival curve restricted to ER-negative reveals association with longer survival (*P* = 0.004). Although the precise underlying biological mechanisms are unclear, it appears that this effect is due to some type of immune system recruitment to fight cancer. Interestingly, however, this effect is reversed in the presence of multiple positive lymph nodes. Indeed, the corresponding Kaplan-Meier curve shown on the right side of [Figure 4](#pcbi-1002920-g004){ref-type="fig"} when restricted to patients with more than five positive lymph nodes demonstrates that the presence of the signature is associated with bad prognosis. This reversal may be explained by the fact that the presence of the lymphocyte-specific signature when lymph nodes are already affected implies that the cancer has obtained a (devastating for the patient) tolerance to this type of immune system recruitment.

![Kaplan-Meier curve of lymphocyte-specific attractor metagenes in breast cancer dataset.\
For ER-negative patients, the expression of the attractor is highly protective (high expression implies longer survival, left). However, when multiple lymph nodes are already affected, the expression of the attractor has a reversed effect on survival. When we restrict the samples to those with more than five positive lymph nodes, higher expression of the lymphocyte-specific attractor implies shorter survival (right), although the association is not significant due to the limited number of samples (76).](pcbi.1002920.g004){#pcbi-1002920-g004}

Other Attractors {#s2f}
----------------

### Chr8q24.3 amplicon attractor {#s2f1}

Amplification in chr8q24 is often considered to be associated with cancer because of the presence of the *MYC* (aka *c-Myc*) oncogene at location 8q24.21. Indeed, *MYC* is one of 157 genes in "amplicon 8q23-q24" previously identified [@pcbi.1002920-Nikolsky1] in an extensive study of the breast cancer "amplicome" derived from 191 samples.

We found, however, that the core of the amplified genes occurs at location 8q24.3 and this is, in fact, our most prominent multi-cancer amplicon attractor. Core genes of the attractor are *PUF60* (aka *FIR*), *EXOSC4*, *SHARPIN*, *HSF1*, *BOP1*, *SLC52A2*. It is known that PUF60 can repress c-Myc via its far upstream element (FUSE), although a particular isoform was found to have the opposite effect [@pcbi.1002920-Matsushita1]. The other genes may also play important roles. For example, *HSF1* (heat shock transcription factor 1) has been associated with cancer in various ways [@pcbi.1002920-Dai1]. It was found [@pcbi.1002920-Lee2] that HSF1 can induce genomic instability through direct interaction with CDC20, a key gene of the mitotic CIN attractor mentioned above (listed in [Table 2](#pcbi-1002920-t002){ref-type="table"}). Furthermore, HSF1 was found [@pcbi.1002920-Meng1] required for the cell transformation and tumorigenesis induced by the ERBB2 (aka HER2) oncogene (see subsequent discussion of *HER2* amplicon) responsible for aggressive breast tumors.

The top ten genes of the chr8q24.3 attractor, ranked by the average of the highest five values of mutual information ([Materials and Methods](#s4){ref-type="sec"}), are shown in [Table 5](#pcbi-1002920-t005){ref-type="table"}. Interestingly, as shown in one of the attractors in Supplementary [Table S1](#pcbi.1002920.s001){ref-type="supplementary-material"}, an aneuploidy attractor involving a whole arm amplification of chr8q is also occasionally present in multiple cancer types, and this 8q whole arm amplification is the most prominent such aneuploidy attractor among all chromosomes.

10.1371/journal.pcbi.1002920.t005

###### List of top ten genes in the chr8q24.3 and HER2 amplicons.

![](pcbi.1002920.t005){#pcbi-1002920-t005-5}

  *chr8q24.3*    *HER2*                         
  ------------- --------- ------- ---- -------- -------
  1              EXOSC4    0.716   1    PGAP3    0.794
  2               PUF60    0.659   2    ERBB2    0.793
  3               BOP1     0.653   3    STARD3   0.768
  4              SLC52A2   0.639   4    MIEN1    0.764
  5              SHARPIN   0.634   5     GRB7    0.718
  6               HSF1     0.616   6    PSMD3    0.602
  7               FBXL6    0.615   7    GSDMB    0.539
  8               CYC1     0.608   8    ORMDL3   0.498
  9               SCRIB    0.552   9    MED24    0.414
  10              GPAA1    0.551   10    MED1    0.400

Furthermore, prognostic associations involving the 8q24.3 amplicon have recently been recognized in various cancers [@pcbi.1002920-Bilal1], [@pcbi.1002920-Peng1].

### Chr17q12 HER2 amplicon attractor {#s2f2}

This amplicon is prominent in breast cancer [@pcbi.1002920-Theillet1] and we also found it present in some samples of ovarian cancer, but not as much in colon cancer. So we initially used the four datasets of breast and ovarian cancer for deriving the attractor. We found that *ERBB2* (aka *HER2*), *STAR3*, *GRB7* and *PGAP3* were the top-ranked genes, consistent with their known presence in the amplicon. We also found that gene *MIEN1* (aka *C17orf37*) was very highly ranked in the two datasets in which its probe set was present. *MIEN1* has recently been identified as an important gene within the 17q12 amplicon in various cancers including prostate cancer [@pcbi.1002920-Dasgupta1]. Therefore, we augmented the choice of datasets to the following seven, of which *MIEN1* is included in five: breast GSE2034, breast GSE32646, breast GSE36771, breast TCGA, ovarian GSE9891, ovarian GSE26193, ovarian TCGA. [Table 5](#pcbi-1002920-t005){ref-type="table"} shows the top ten genes ranked by the average of the top five scores of mutual information ([Materials and Methods](#s4){ref-type="sec"}) in the seven datasets for each gene. The results suggest that the above-mentioned five genes, including *MIEN1*, are consistently strongly co-expressed, and therefore are likely "driver" genes in the amplicon.

In addition to the narrow *HER2* amplicon, it is known that sometimes a large amplicon extends to more than a million bases containing both *HER2* as well as *TOP2A* (one of the genes of the mitotic CIN attractor) at 17q21 [@pcbi.1002920-Arriola1]. We have observed that *TOP2A* indeed appears among the top 50 genes in terms of its association with the attractor in breast cancer. *HER2*/*TOP2A* co-amplification has been linked with better clinical response to therapy.

### Estrogen receptor breast cancer attractor {#s2f3}

We found this attractor clearly present only in breast cancer, and therefore we derived it using six breast cancer datasets (GSE2034, GSE3494, GSE31448, GSE32646, GSE36771, breast TCGA). [Table 6](#pcbi-1002920-t006){ref-type="table"} shows the top 50 genes ranked by the average mutual information ([Materials and Methods](#s4){ref-type="sec"}) in these datasets, revealing that genes *AGR3, CA12*, *AGR2*, *GATA3*, *FOXA1*, *MLPH* and *TBC1D9* are strongly co-expressed with the estrogen receptor *ESR1* in the attractor. However, this co-expression is not as uniform as in the other attractors. For example, the progesterone receptor PGR appear in the list, but in reality it can be underexpressed even if the estrogen receptor ESR1 is not.

10.1371/journal.pcbi.1002920.t006

###### Top 50 genes of the estrogen receptor breast cancer attractor.
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  Rank    Gene Symbol   Avg MI   Rank   Gene Symbol   Avg MI
  ------ ------------- -------- ------ ------------- --------
  1          AGR3       0.847     26       ERBB4      0.393
  2          CA12       0.616     27        AR        0.383
  3          FOXA1      0.613     28       P4HTM      0.383
  4          GATA3      0.585     29      SLC44A4     0.380
  5          MLPH       0.580     30       KDM4B      0.375
  6          AGR2       0.570     31       GFRA1      0.374
  7          ESR1       0.543     32       MAPT       0.370
  8         TBC1D9      0.540     33        MYB       0.364
  9          XBP1       0.460     34       DACH1      0.359
  10         ANXA9      0.456     35      SLC7A8      0.359
  11         PRR15      0.452     36      MAGED2      0.358
  12        SCUBE2      0.444     37       FBP1       0.357
  13         FSIP1      0.438     38      SLC22A5     0.355
  14         TFF3       0.429     39       CMBL       0.346
  15         SPDEF      0.429     40      DYNLRB2     0.346
  16         NAT1       0.428     41     C6orf211     0.342
  17         ABAT       0.423     42       GREB1      0.342
  18        CCDC170     0.422     43       SIDT1      0.338
  19        DNALI1      0.418     44      TTC39A      0.330
  20         DEGS2      0.415     45      FAM214A     0.326
  21        DNAJC12     0.411     46       IL6ST      0.324
  22        SLC39A6     0.406     47       CXXC5      0.323
  23         CAPN8      0.399     48      ACADSB      0.323
  24         TFF1       0.397     49      CELSR1      0.322
  25         THSD4      0.395     50      CLSTN2      0.322

Comparison with Other Unsupervised Algorithms {#s2g}
---------------------------------------------

The scope of the algorithm identifying attractor metagenes is different from that of other unsupervised methods, which are usually aimed at identifying subtypes or mutually exclusive clusters. Nevertheless, it is interesting to find to what extent other algorithms can produce multiple cancer signatures each of which appears in nearly identical form across different types. We applied three widely used methods, k-means clustering, principal component analysis and hierarchical clustering on the six cancer datasets used in this paper. In all cases, we listed the top fifty genes in each cluster and applied the same clustering algorithm as in the main text to find common genes among them and group them together. The results are shown in Supplementary [Text S2](#pcbi.1002920.s009){ref-type="supplementary-material"} and Supplementary [Tables S5](#pcbi.1002920.s005){ref-type="supplementary-material"}, [S6](#pcbi.1002920.s006){ref-type="supplementary-material"}, [S7](#pcbi.1002920.s007){ref-type="supplementary-material"}. We found that, in all cases, these well-established methods cannot identify multiple universal metagenes common in all six tested datasets.

Using Attractor Metagenes as Proxies of Biomolecular Events {#s2h}
-----------------------------------------------------------

A biomolecular event, whether it is present in multiple cancer types or it is cancer specific, can be represented by a "consensus attractor metagene" after analyzing multiple datasets. To generate such consensus attractors, we use genes that were profiled by at least three of the six datasets, then rank individual genes in terms of their average mutual information ([Materials and Methods](#s4){ref-type="sec"}) with the corresponding attractor metagenes across all datasets in which the gene was profiled.

For example, [Figure 5](#pcbi-1002920-g005){ref-type="fig"} contains scatter plots from four different rich breast cancer datasets connecting the mitotic CIN and estrogen receptor attractors. It has previously been reported [@pcbi.1002920-Birkbak1] that breast tumors with high chromosomal instability are predominantly of the estrogen receptor negative phenotype. Although these scatter plots cannot be used for precise conclusions, they do suggest in all cases that ER-negative tumors have high mitotic chromosomal instability (or equivalently that low chromosomal instability implies that the tumor is ER-positive). The reverse relationship, however, is not as clear.

![Scatter plots demonstrating the relationship between mitotic CIN attractor and estrogen receptor attractor in breast cancer.\
The two metagenes were defined to be "consensus attractors" after ranking individual genes in terms of their average mutual information with the corresponding attractor metagenes, across all datasets, and selecting the genes having average mutual information greater than 0.5. These criteria led to 59 genes in the consensus mitotic CIN attractor (the top 59 genes in [Table 2](#pcbi-1002920-t002){ref-type="table"}), and *AGR3, ESR1*, *CA12*, *AGR2*, *GATA3*, *FOXA1*, *MLPH* and *TBC1D9* (the top eight genes in [Table 6](#pcbi-1002920-t006){ref-type="table"}) in the consensus estrogen receptor breast cancer attractor. These scatter plots reveal that ER-negative breast tumors have high mitotic chromosomal instability, but not necessarily vice versa.](pcbi.1002920.g005){#pcbi-1002920-g005}

Discussion {#s3}
==========

Gene expression analysis has resulted in several cancer types being further classified into subtypes labeled, e.g. as "mesenchymal" or "proliferative." Such characterizations, however, may sometimes simply reflect the presence of the mesenchymal transition attractor or the mitotic chromosomal instability attractor, respectively, in some of the analyzed samples. Similar subtype characterizations across cancer types often share several common genes, but the consistency of these similarities has not been significantly high.

By contrast, using an unconstrained algorithm independent of subtype classification or dimensionality reduction, we identified several attractors exhibiting remarkable consistency across many cancer types, suggesting that each of them represents a precise biological phenomenon present in multiple cancers.

We found that the mesenchymal transition attractor is significantly present only in samples whose stage designation has exceeded a threshold, but not in all of such samples. On the other hand, the absence of the mesenchymal transition attractor in a profiled high-stage sample (or the absence of the mitotic chromosomal instability attractor in a profiled high-grade sample) does not necessarily mean that the attractor is not present in other locations of the same tumor. Indeed, it is increasingly appreciated [@pcbi.1002920-Gerlinger1] that tumors are highly heterogeneous. Therefore it is possible for the same tumor to contain components, in which, e.g., some are migratory having undergone mesenchymal transition, some other ones are highly proliferative, etc. If so, attempts for subtype classification based on one particular site in a sample may be confusing.

Existing molecular marker products make use of multigene assays that have been derived from phenotypic associations in particular cancer types. For breast cancer, biomarkers such as Oncotype DX [@pcbi.1002920-Paik1] and Mammaprint [@pcbi.1002920-vantVeer1] contain several genes highly ranked in our attractors. For example, most of the genes used for the Oncotype DX breast cancer recurrence score directly converge to one of our identified attractors: *MMP11* to the mesenchymal transition attractor; *MKI67* (aka *Ki-67*), *AURKA* (aka *STK15*), *BIRC5* (aka *Survivin*), *CCNB1*, and *MYBL2* to the mitotic CIN attractor; *CD68* to the lymphocyte-specific attractor; *ERBB2* and *GRB7* to the *HER2* amplicon attractor; and *ESR1*, *SCUBE2*, *PGR* to the estrogen receptor attractor.

We envision, instead, a multi-cancer biomarker product that will include detection of the level of expression of each of the key attractor metagenes. These levels would need to be combined in different ways in different cancer types, but each of the metagenes would indicate the same attribute and the contributions of each component will be cleanly distinguished. Even though molecular marker genes in some existing products are already separated into groups that are related to our attractor designation, any improvement in diagnostic, prognostic, or predictive accuracy resulting from better such group designation and better choice of genes in each group would be highly desirable. We hope that the identification of the attractors of cancer, as presented here, will be valuable in that regard.

Materials and Methods {#s4}
=====================

The full code of the attractor finding algorithm is publicly available in the Sage Bionetworks Synapse platform at <https://synapse.sagebase.org/#Synapse:syn1446295>. In addition, we provide a pseudo-code in Supplementary [Text S3](#pcbi.1002920.s010){ref-type="supplementary-material"}.

General Attractor Finding Algorithm {#s4a}
-----------------------------------

We chose the association measure between genes to be a power function with exponent *a* of a normalized estimated information theoretic measure of the mutual information [@pcbi.1002920-Cover1] with minimum value 0 and maximum value 1 (see "Mutual information estimation" below; more sophisticated related association measures [@pcbi.1002920-Reshef1] can also be used, but computational complexity will be prohibitive). In other words, , in which the exponent can be any nonnegative number. The value of is set to zero if the Pearson correlation between the two genes is negative. Each iteration defines a new metagene in which the weight for gene is equal to where is the immediately preceding metagene. The process is repeated until the magnitude of the difference between two consecutive weight vectors is less than a threshold, which we chose to be equal to 10^−7^.

At one extreme, if is sufficiently large then each of the seeds will create its own single-gene attractor because all other genes will always have near-zero weights. In that case, the total number of attractors will be equal to the number of genes. At the other extreme, if is zero then all weights will remain equal to each other representing the average of all genes, so there will only be one attractor. The higher the value of , the "sharper" (more focused on its top gene) each attractor will be and the higher the total number of attractors will be. As the value of is gradually decreased, the attractor from a particular seed will transform itself, occasionally in a discontinuous manner, thus providing insight into potential related biological mechanisms.

We empirically found that an appropriate choice of (in the sense of maximizing the strength of the attractor, as defined below) for general attractors is around 5, in which case there will typically be approximately 50 to 150 resulting attractors, each resulting from many attractee genes. An alternative to the power function can be a sigmoid function with varying steepness, but we found that the consistency of the resulting attractors was worse in that case.

As mentioned in the [Introduction](#s1){ref-type="sec"}, an attractor metagene can also be interpreted as a set of the top genes of the attractor, i.e., a gene set that includes only the genes that are significantly associated with the attractor. One empirical choice for such a gene set would be to include only the genes whose mutual information (or the z-score thereof) with the attractor metagene exceeds a particular threshold. In fact, the attractor finding algorithm itself can be designed to discover "attractor gene sets," without assigning weights to genes. In that case, metagenes are defined as simple averages of the genes in a gene set, and each iteration leads to a new gene set consisting of the new set of top-ranked genes in terms of their association with the previous metagene (gene set sizes can be constant or adaptively changing in various ways). We found, however, that such a method has the disadvantage of occasionally leading to attractors with significant overlap, which requires additional post-processing steps.

Identified attractors can be ranked in various ways. The "strength of an attractor" can be defined as the mutual information between the *n* ^th^ top gene of the attractor and the attractor metagene. Indeed, if this measure is high, this implies that at least the top *n* genes of the attractor are strongly co-expressed. We selected *n* = 10 as a reasonable choice, not too large, but sufficiently so to represent a real complex biological phenomenon of co-expression of at least ten genes. For amplicons, *n* = 5 is sufficient to ensure that the oncogenes are included in the co-expression). We use these choices when referring to the strength of an attractor.

The top genes of many among the found attractors are genomically localized. In that case the biomolecular event that they represent is often the presence of a particular copy number variation. In the cancer datasets that we tried, this phenomenon almost always corresponds to a local amplification event known as an amplicon. We therefore also devised a related amplicon-finding algorithm, custom-designed to identify localized amplicon-representing attractor metagenes, described below.

Genomically Localized Attractor Finding Algorithm {#s4b}
-------------------------------------------------

To identify genomically localized attractors -- almost always amplicons -- we use the same algorithm but for each seed gene we restrict the set of candidate attractor genes to only include those in the local genomic neighbourhood of the gene, and we optimize the exponent a so that the strength of the attractor is maximized. Specifically, we sort the genes in each chromosome in terms of their genomic location and we only consider the genes within a window of size 51, i.e., with 25 genes on each side of the seed gene. We further optimize the choice of the exponent for each seed, by allowing to range from 1.0 to 6.0 with step size of 0.5 and selecting the attractor with the highest strength.

Because the set of allowed genes is different for each seed, the attractors will be different from each other, but "neighbouring" attractors will usually be very similar to each other. Therefore, following exhaustive attractor finding from each seed gene in a chromosome, we apply a filtering algorithm to only select the highest-strength attractor in each local genomic region, as follows: For each attractor, we rank all the genes in terms of their mutual information with the corresponding attractor metagene and we define the range of the attractor to be the chromosomal range of its top 15 genes. If there is any other attractor with overlapping range and higher strength, then the former attractor is filtered out. This filtering is done in parallel, so elimination of attractors occurs simultaneously.

Mutual Information Estimation {#s4c}
-----------------------------

Assuming that the continuous expression levels of two genes and are governed by a joint probability density with corresponding marginal and , the mutual information is defined as the expected value of . It is a non-negative quantity representing the information that each one of the variables provides about the other. The pairwise mutual information has successfully been used as a general measure of the correlation between two random variables. We compute mutual information with a spline-based estimator [@pcbi.1002920-Daub1] using six bins in each dimension. This method divides the observation space into equally spaced bins and blurs the boundaries between the bins with spline basis functions using third-order B-splines. We further normalize the estimated mutual information by dividing by the maximum of the estimated and , so the maximum possible value of is 1.

Pre-processing Gene Expression Datasets {#s4d}
---------------------------------------

We used Level 3 data when directly available, and imputed missing values using a k-nearest-neighbour algorithm with k = 10, as implemented in R [@pcbi.1002920-Troyanskaya1]. We normalized the other datasets on the Affymetrix platform using the RMA algorithm as implemented in the *affy* package in Bioconductor [@pcbi.1002920-Gautier1]. To avoid biasing attractor convergence with multiple correlated probe sets of the same gene, we summarized the probe set-level expression values into the gene-level expression values by taking the mean of the expression values of probe sets for the same genes. We used the annotations for the probe sets given in the *jetset* package [@pcbi.1002920-Li1].

To investigate the associations between the attractor metagene expression and the tumor stage and grade, we used the following annotated gene expression datasets. For stage association: Breast (GSE3893), TCGA Ovarian, Colon (GSE14333). For grade association: Breast (GSE3494), TCGA Ovarian, Bladder (GSE13507). For Breast GSE3494 we used only the samples profiled by U133A arrays. For Breast GSE3893 we combined two platforms by taking the intersections of the probes in the U133A and the U133Plus 2.0 arrays. For datasets profiled by Affymetrix platforms all the datasets were normalized using the RMA algorithm. For Bladder GSE13507 normalization was done as provided in the GEO.

*P* Value Evaluation {#s4e}
--------------------

*P* values for gene set enrichment were evaluated with the cumulative hypergeometric distribution using the total number of genes in each dataset.

The significance of the consistency of the mesenchymal transition and mitotic CIN attractors was evaluated as follows: Supplementary [Table S1](#pcbi.1002920.s001){ref-type="supplementary-material"} contains 210 gene sets from six cancer datasets. Each of the gene sets contains 50 genes. The mesenchymal transition metagene has eight genes (COL5A2, COL1A2, SPARC, CTSK, FBN1, VCAN, AEBP1, SERPINF1) common across all six datasets. The mitotic CIN metagene has 13 common genes (CENPA, DLGAP5, KIF2C, CCNB2, MELK, CCNA2, KIF20A, HJURP, NUSAP1, BUB1, TTK, KIF11, NCAPH) across all six datasets. To evaluate the significance of the consistency across the six datasets, we randomly generated 210 gene sets with the same sizes as those in the Table. In other words, we randomly selected 50 genes out of the 11,395 common genes to generate a random gene set. We created 210 such random gene sets, and then assigned them to six different datasets according to the settings in the Table. We then performed the clustering algorithm described in [Materials and Methods](#s4){ref-type="sec"}. Each time, we counted the maximum number of genes common in all six datasets, and we repeated this process ten million times. This constitutes a conservative way of evaluating consistency, in the sense that for each random experiment we only record the maximum number of common genes in the gene set cluster, and we created random gene sets using only the common genes in the six datasets. In these ten million experiments, it never occurred that more than one gene was common in all six datasets. Therefore, the corresponding *P* value for both the mesenchymal transition metagene as well as the mitotic CIN metagene is less than 10^−7^, and is in fact much lower than that given the large number (8 and 13 respectively) of the common genes.

Supporting Information {#s5}
======================
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